Neurocrine Biosciences (NBIX), developer of treatments for neurological and endocrine based diseases, said late Friday that data from several long-term...
Neurocrine Biosciences (NBIX) was steady in late Tuesday trading after saying it will present new data analysis supporting the long-term effects of its...
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...
Price: 95.00, Change: +0.05, Percent Change: +0.05 ...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 10/16/2019 4 |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Vice President-Information Technology & Operations | Bill Wilson |
| Price Open | $92.89 |
| Previous Close | $93.49 |
| 52 Week Range | $64.72 - 116.48 |
| Market Capitalization | $8.6 B |
| Shares Outstanding | 91.6 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/04/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 694.85 |
| Earnings per Share | $0.87 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 2.98% |
| Return on Equity | 3.97% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
